Novel Adenovirus Vectors for Biodefense Vaccines

用于生物防御疫苗的新型腺病毒载体

• 批准号: 7054290
• 负责人: C. RICHTER KING
• 金额: $ 43.35万
• 依托单位: GENVEC, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-15 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7054290
• 关键词: Adenoviridae; antigens; bioterrorism /chemical warfare; immune response; neutralizing antibody; serotyping

DESCRIPTION (provided by applicant): This proposal is designed to create technology that can be rapidly applied to the generation of novel vaccines against biodefense threat agents. Antigens that have the potential to provide protection against a biodefense threat have been identified or are emerging from independent research. This SBIR proposal is designed to identify technology platforms that can rapidly convert such antigenic genes into potent vaccines for clinical testing. Existing adenovirus vaccine platforms promote strong balanced immune responses [including mucosal responses] and there is a wealth of existing know-how for GMP production, manufacturing and quality testing. The objectives of this SBIR proposal address a potential weakness in current adenovirus vector technology based on Adenovirus serotype 5 (Ad5). Previous exposure and resulting immune response to Ad5 viruses or vectors can limit the potency of Ad5 vaccine vectors. Consequently, immunization for HIV may well render Ad5 based vectors less potent for other applications. A central goal of this application is to broaden the applicability of adenovirus vector technology by establishing and testing new Advector vaccine technology platforms. We, and others,are currently exploring non-Ad5 technology for vaccine applications. Unfortunately for biodefense, these first non-Ad5 technologies will also be used in the generation of HIV or malaria vaccines. In this application, we propose to develop additional non-Ad5 and non-Ad35 technologies for biodefense vaccine application. This SBIR is aligned with the effort to produce broadly applicable or "Universal," biodefense technology.

描述（由申请人提供）：本提案旨在创建可快速应用于生成针对生物防御威胁因子的新型疫苗的技术。具有提供针对生物防御威胁的保护的潜力的抗原已经被鉴定或正在从独立研究中出现。这项SBIR提案旨在确定能够快速将此类抗原基因转化为用于临床测试的有效疫苗的技术平台。现有的腺病毒疫苗平台促进了强平衡的免疫应答[包括粘膜应答]，并且存在丰富的GMP生产、制造和质量测试的现有技术。该SBIR提案的目的是解决基于腺病毒血清型5（Ad5）的当前腺病毒载体技术的潜在弱点。先前的暴露和对Ad5病毒或载体产生的免疫应答可以限制Ad5疫苗载体的效力。因此，针对HIV的免疫很可能使基于Ad5的载体对于其他应用不那么有效。本申请的中心目标是通过建立和测试新的Advector疫苗技术平台来拓宽腺病毒载体技术的适用性。我们和其他人目前正在探索用于疫苗应用的非Ad5技术。不幸的是，对于生物防御来说，这些第一批非Ad5技术也将用于生产艾滋病毒或疟疾疫苗。在本申请中，我们建议开发用于生物防御疫苗应用的额外的非Ad5和非Ad35技术。该SBIR与生产广泛适用或“通用”生物防御技术的努力相一致。